Zacks: Brokerages Anticipate Meridian Bioscience, Inc. (NASDAQ:VIVO) Will Announce Quarterly Sales of $99.55 Million

Brokerages expect Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating) to post sales of $99.55 million for the current quarter, according to Zacks. Two analysts have issued estimates for Meridian Bioscience’s earnings, with the highest sales estimate coming in at $111.00 million and the lowest estimate coming in at $88.10 million. Meridian Bioscience reported sales of $85.26 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 16.8%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Meridian Bioscience will report full-year sales of $337.62 million for the current year, with estimates ranging from $322.90 million to $352.34 million. For the next year, analysts expect that the firm will report sales of $328.05 million, with estimates ranging from $325.50 million to $330.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVOGet Rating) last issued its quarterly earnings results on Friday, February 4th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.10. Meridian Bioscience had a return on equity of 18.45% and a net margin of 19.14%. The company had revenue of $88.34 million for the quarter, compared to analyst estimates of $73.75 million. During the same quarter last year, the company posted $0.65 EPS.

Several equities analysts have recently issued reports on VIVO shares. StockNews.com started coverage on Meridian Bioscience in a research note on Thursday, March 31st. They issued a “buy” rating on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Meridian Bioscience in a research report on Friday, April 8th. Finally, Zacks Investment Research upgraded Meridian Bioscience from a “hold” rating to a “buy” rating and set a $31.00 price objective on the stock in a research report on Wednesday, April 13th.

In other news, EVP Lourdes Weltzien sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 15th. The stock was sold at an average price of $25.60, for a total value of $512,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew S. Kitzmiller acquired 4,028 shares of the company’s stock in a transaction dated Friday, February 25th. The stock was acquired at an average cost of $24.87 per share, for a total transaction of $100,176.36. The disclosure for this purchase can be found here. Insiders own 2.30% of the company’s stock.

Large investors have recently made changes to their positions in the company. Horan Securities Inc. acquired a new position in shares of Meridian Bioscience in the 4th quarter valued at about $33,000. Spire Wealth Management acquired a new position in Meridian Bioscience during the 4th quarter worth approximately $47,000. ProShare Advisors LLC acquired a new position in Meridian Bioscience during the 4th quarter worth approximately $217,000. Everence Capital Management Inc. acquired a new position in Meridian Bioscience during the 1st quarter worth approximately $221,000. Finally, AlphaCrest Capital Management LLC acquired a new position in Meridian Bioscience during the 3rd quarter worth approximately $229,000. 94.50% of the stock is currently owned by institutional investors.

Shares of VIVO opened at $25.00 on Wednesday. Meridian Bioscience has a 52-week low of $17.00 and a 52-week high of $28.72. The firm has a fifty day simple moving average of $25.98. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.59 and a current ratio of 4.08. The company has a market cap of $1.09 billion, a price-to-earnings ratio of 18.38 and a beta of 0.34.

Meridian Bioscience Company Profile (Get Rating)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Featured Stories

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.